U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)
Phase of Trial: Phase IV
Latest Information Update: 17 May 2018
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms U-ACT-AFTER
- Sponsors Roche
- 10 May 2018 Status changed from active, no longer recruiting to completed.
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2016 Status changed from active, no longer recruiting to recruiting.